The company's holding of its own shares at the end of 1999 was 4,514,059 B shares, corresponding to 5.98% of the total capital stock as of the end of 1999. A total of 523,000 B shares were repurchased in the period 3 November - 31 December 1999.
As of 3 November 1999, Novo Nordisk A/S' holding of its own shares was 3,991,059 B shares (following a downward adjustment of 11,620 B shares issued as employee shares). The average price of the 536,000 B shares repurchased after 3 November 1999 is DKK 967.78 per share. No treasury shares were sold in the period under review.
Novo Nordisk A/S is the world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzymes. Headquartered in Denmark, Novo Nordisk employs approximately 15,000 people in 61 countries and markets its products in 179 countries. Its B shares are listed on the stock exchanges in Copenhagen, London and Zurich. Its ADSs are listed on the New York Stock Exchange under the symbol "NVO". For further company information, visit Novo Nordisk on the World Wide Web at http://www.novo.dk
For further information please contact:
NN
Communications & Design
Media:
Elin K Hansen
Phone (direct) : (+45) 4442 3450
Elin K Hansen
Phone (direct) : (+45) 4442 3450
Media in North America:
Susan Toth Jackson
Phone: (+1) 212-867-0123
Susan Toth Jackson
Phone: (+1) 212-867-0123
Investors:
Michael Steen-Knudsen
Phone (Direct): (+45) 4442 6048
Michael Steen-Knudsen
Phone (Direct): (+45) 4442 6048
Investors:
Carsten Bøss
Phone: (direct) (+45) 4442 6047
Carsten Bøss
Phone: (direct) (+45) 4442 6047
Investors in North America:
Peter Lundby Hansen
Phone: (+1) 212-878-9607
Peter Lundby Hansen
Phone: (+1) 212-878-9607